您现在位置： -医药产业 >> 研究报告 >> English reports >> English reports >> 浏览医药行业研究报告
Second line drugs for nonsmall-cell lung cancer report
[关键字]： nonsmall-cell lung cancer,Docetaxel,Gefitinib
讯：
Market report of second line drugs for nonsmall-cell lung cancer (NSCLC)
Publisher: Orient Health Electronic Commercial(Beijing)co.,Ltd
Published: June 2007
Format: Adobe PDF
Price: US$ 1,200
Contact: Mr. Bian chenghua Ms. Wu huifang
Tel.: 86-10-68012929-2116/2101 Fax: 86-10-68052525
E-mail: bianch@healthoo.com wuhf@healthoo.com
Table of contents
1．Overview of Chinese anticancer market
2．Aanalysis on second line drugs for nonsmall-cell lung cancer
Docetaxel
Gefitinib
Pemetrexed
Appendix: Reatail prices of the three drugs
Tables or figures
1 Sales values of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
2 Sales amount of second line drugs for nonsmall-cell lung cancer in sample hospitals from 2005 to 2006
3 Sales statistic of Docetaxel with different specifications from 2005 to 2006
4 Detail statistic of Docetaxel in sample hospitals in 2005
5 Detail statistic of Docetaxel in sample hospitals in 2006
6 Detail statistic of Gefitinib in sample hospitals from 2005 to 2006
7 Sales statistic of Pemetrexed in sample hospitals in 2006
8 Reatail prices of the three drugs
|
||||||||||||||||